BSX vs. IDXX: Boston Scientific vs. IDEXX Laboratories Stock Comparison

Company Profile

Boston Scientific (BSX) and IDEXX Laboratories (IDXX) are both classified in the Health Care Equipment sub-industry within the broader Health Care Equipment & Supplies industry, placing them in the closest GICS peer bucket.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

IDEXX Laboratories (IDXX) has an aggressive beta of 1.44, indicating higher sensitivity to broad-market moves, while Boston Scientific (BSX) is defensive at 0.57 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Boston Scientific (BSX) is heavily traded at around 19.73M shares per day, whereas IDEXX Laboratories (IDXX) sees a more moderate 564.80K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

IDEXX Laboratories (IDXX) at 68.93% clears its industry range for ROE, a sharper capital-efficiency signal than Boston Scientific (BSX) at 14.12%, which is closer to a typical peer reading.

For every dollar of sales, both Boston Scientific (BSX) at 16.62% and IDEXX Laboratories (IDXX) at 25.36% retain more as net profit than most peers, landing in the top net margin quartile of their industries.

Both Boston Scientific (BSX) at 19.05% and IDEXX Laboratories (IDXX) at 33.14% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Boston Scientific (BSX) at 19.87% and IDEXX Laboratories (IDXX) at 10.42% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Boston Scientific (BSX) at 55.20% sits in the top EPS growth quartile, while IDEXX Laboratories (IDXX) at 22.59% is closer to the peer norm — faster per-share earnings growth for BSX.

Growth Metrics

Financial Strength

Both Boston Scientific (BSX) at 1.37 and IDEXX Laboratories (IDXX) at 1.19 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Boston Scientific (BSX) at 0.46 and IDEXX Laboratories (IDXX) at 0.52 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Boston Scientific (BSX) nor IDEXX Laboratories (IDXX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Boston Scientific (BSX) nor IDEXX Laboratories (IDXX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Boston Scientific (BSX) at 18.04 sits in the cheaper P/E ratio quartile, while IDEXX Laboratories (IDXX) at 45.56 is closer to its industry’s usual earnings multiple — a discount for BSX, though growth and earnings durability still matter.

Boston Scientific (BSX) at 2.94 prices around its industry’s typical P/S ratio, while IDEXX Laboratories (IDXX) at 11.42 clears its benchmark range — IDXX looks notably rich on sales.

Boston Scientific (BSX) at 2.42 sits near its industry’s typical P/B ratio, while IDEXX Laboratories (IDXX) at 28.50 prices above its benchmark range — IDXX looks rich relative to book.

Valuation Metrics